Steven M. Willi

faculty photo
Associate Professor of Pediatrics at the Children's Hospital of Philadelphia
Department: Pediatrics

Contact information
Division of Endocrinology
and Diabetes
The Children's Hospital
of Philadelphia
34th & Civic Center Blvd.
Philadelphia, PA 19104
Office: (215) 590-3618
Fax: (215) 590-3053
BA (Chemistry)
Johns Hopkins University, 1981.
MD (Medicine)
Johns Hopkins University, 1985.
Permanent link

Description of Itmat Expertise

Dr. Willi is interested in therapeutics for type 1 and type 2 diabetes and has performed a number of physiologic studies in the etiology and characterization of diabetes in children.
Current studies include three trials on the delay of progression of type 1 diabetes and a multicenter trial to examine the optimal therapeutics for type 2 diabetes in children.

Selected Publications

Jago R, Drews KL, Otvos JD, Foster GD, Marcus MD, Buse JB, Mietus-Snyder M, Willi SM; HEALTHY Study Groups: Effect of Relative Weight Group Change on Nuclear Magnetic Resonance Spectroscop Derived Lipoprotein Particle Size and Concentrations Among Adolescents. J Pediatr 164: 1091-1098, May 2014.

Greeley NR, Regner S, Willi S, Lynch DR.: Cross-sectional analysis of glucose metabolism in Friedreich ataxia. J Neurol Sci. 342(1-2): 29-35, 2014.

Gitelman SE, Gottlieb PA, Rigby MR, Felner E, Willi SM, Fisher LK, Moran A, Gottschalk M, Moore WV, Pinckney A, Keyes-Elstein L, AggarwalS, Phippard D, Sayre PH, Ding L, Bluestone JA, Ehlers MR, the START Study Team: Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial. The Lancet Diabetes & Endocrinology 4: 306-316, December 2013.

Rigby MR, DiMeglio L, Rendell MS, Felner E, Dostou JM, Gitelman SE, Patel CM, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM et al: Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL Study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. The Lancet Diabetes & Endocrinology(4), 284-294, December 2013.

Mietus-Snyder M, Drews KL, Otvos JD, Willi SM, Foster GD, Jago R, Buse JB; HEALTHY Study Group: Low-Density Lipoprotein Cholesterol versus Particle Number in Middle School Children. J Pediatr 163: 355-62, August 2013.

Arslanian S, Pyle L, Washington G, Payan M, Bacha F, Caprio S, Haymond MW, Levitsky LL, Goland R, White NH, Willi SM.: Effects of metformin, metformin plus rosiglitazone, and metformin plus lifestyle on insulin sensitivity and β-cell function in TODAY. Diabetes Care 36(6): 1749-57, June 2013.

Montgomery KA, Ratcliffe SJ, Baluarte HJ, Murphy KM, Willi S, Lipman TH.: Implementation of a clinical practice guideline for identification of microalbuminuria in the pediatric patient with type 1 diabetes. Nurs Clin North Am. 48(2): 343-52, June 2013.

White NH, Pyle L, Willi SM, Pham T, Chernausek SD, Goland R, Berrie N, Hale DE, Haymond MW, Nadeau KJ, Narasimhan S.: Safety and tolerability of the treatment of youth-onset type 2 diabetes: the TODAY experience. Diabetes Care 36(6): 1765-71, June 2013.

Lebastchi J, Deng S, Lebastchi AH, Beshar I, Gitelman S, Willi S, Gottlieb P, Akirav EM, Bluestone JA, Herold KC: Immune Therapy and β-Cell Death in Type 1 Diabetes. Diabetes 62(5): 1676-1680, May 2013.

Rafalson L, Pham TH, Willi SM, Marcus M, Jessup A, Baranowski T: The association between acanthosis nigricans and dysglycemia in an ethnically diverse group of eighth grade students. Obesity 21(3): E328-E333, March 2013.

back to top
Last updated: 07/22/2014
The Trustees of the University of Pennsylvania